NPPB, natriuretic peptide B, 4879

N. diseases: 193; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure. 29959987 2018
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure. 29959987 2018
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. 24535859 2014
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. 24535859 2014
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human [B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure]. 19650993 2009
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human [B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure]. 19650993 2009
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. 16777915 2006
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. 16777915 2006
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). 16762801 2006
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). 16762801 2006
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. 16101196 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. 16360360 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. 16101196 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. 16360360 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. 15732037 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. 15860969 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Nesiritide: past, present, and future. 16333235 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Nesiritide: past, present, and future. 16333235 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. 15732037 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. 15860969 2005
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). 12628948 2003
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). 12628948 2003
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. 11136700 2001
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Biomarker disease CTD_human Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. 11136700 2001
CUI: C1959583
Disease: Myocardial Failure
Myocardial Failure
0.300 Therapeutic disease CTD_human Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. 11279304 2000